
BBIO Stock Forecast & Price Target
BBIO Analyst Ratings
Bulls say
BridgeBio Pharma is supported by Attruby’s strong commercial execution, with Q3 US sales of $253MM beating consensus by 2% and growing 14% sequentially and 134% year over year, while de-stocking was minimal and frontline share continued to expand. Its positive outlook is further reinforced by a late-stage pipeline with multiple near-term catalysts: BBP-418, encaleret, and infigratinib all posted compelling Phase III data, have clear regulatory paths, and target large orphan markets with blockbuster potential. BridgeBio also ended Q3 with $1.5B in cash and expects operating losses to narrow from $350-375MM in 2026 to about $250MM in 2027, supporting commercialization momentum and a path to profitability in early-2028.
Bears say
BridgeBio Pharma is exposed to severe balance-sheet risk because it carries about $1.9B in debt and only limited cash reserves, leaving little cushion if late-stage programs underperform. Its outlook is further pressured by the possibility that Attruby cannot meaningfully penetrate the ATTR-CM market amid competitive pressure and weak clinical adoption, while infigratinib faces adoption risk in the US market and other pipeline assets may fail to show adequate safety and efficacy. If these commercialization and development risks materialize, the company may struggle to service lenders or sustain operations, raising bankruptcy risk.
This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
BBIO Analyst Forecast & Price Prediction
Start investing in BBIO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About BridgeBio Pharma Inc (BBIO) Forecast
BBIO Analyst Forecast & Price Prediction
Start investing in BBIO
Order type
Buy in
Order amount
Est. shares
0 shares